Other languages Actinogen Medical Limited

Equities

ACW

AU000000ACW3

Market Closed - Australian S.E. Other stock markets 02:10:24 2024-07-12 am EDT			5-day change	1st Jan Change
0.071 ^AUD	-4.05%		+9.23%	+222.73%

Jul. 02	Actinogen Medical Expects Results from XanaCIDD Phase 2a Clinical Trial in August; Shares Down 6%	MT
Jun. 26	Actinogen Medical Limited Announces the Peer-Reviewed Publication of its Phase 2a Biomarker	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Actinogen Medical Expects Results from XanaCIDD Phase 2a Clinical Trial in August; Shares Down 6%	Jul. 02
Actinogen Medical Limited Announces the Peer-Reviewed Publication of its Phase 2a Biomarker	Jun. 26
Actinogen Medical's Xanamem Drug 'Potentially Slows' Progression of Alzheimer's Disease	Jun. 26
Actinogen Medical Opens AU$3.9 Million Entitlement Offer; Shares Down 7%	May. 15
Actinogen Medical Raising Up to AU$8.9 Million for Advancing Trial, Working Capital; Shares Fall 24%	May. 02
Actinogen Medical Limited Announces the Full Enrolment of 167 Participants in the Company's XanaCIDD Phase 2A Clinical Trial in Patients with Cognitive Importive in Major Depressant Disorder	Apr. 22
Actinogen Medical Limited Announces First Patient Treated in XanaMIA Phase 2b Alzheimer's Disease Trial	Apr. 15
Actinogen Doses First Patient in Phase 2b Alzheimer’s Disease Trial; Shares Rally 16%	Apr. 14
Actinogen Medical Notifies of Errors on M&A Slide in Recent Presentation	Mar. 25
Actinogen Medical Initiates Final Enrolment Phase for XanaCIDD Depression Trial; Shares Rise 3%	Mar. 07
Actinogen Medical Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 25
Actinogen Medical Secures UK Innovation Passport for Alzheimer’s Disease Treatment	Feb. 15
Actinogen Medical Limited Announces Enrolment in the XanaCIDD Phase 2A Proof-Of-Concept Trial	Nov. 28
AActinogen Medical Limited to Present Progress on Phase 2 Trials At the Bio Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease Conference, Boston	23-10-13
Actinogen Medical Redesigns Phase 2b Trial of Alzheimer's Disease Drug	23-09-27
Actinogen Medical Limited Announces Optimization of XanaMIA Phase 2b Trial in Patients with Mild-to-Moderate Alzheimer's Disease to Reduce Cost and Time to Initial Results	23-09-26
Actinogen Medical Completes AU$10 Rights Issue	23-09-07
Actinogen Medical Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30
Actinogen Medical to Raise AU$10 Million for Clinical Trial Program; Shares Down 22%	23-08-02
Actinogen Medical Limited to Present Progress on Cognitive Impairment in Depression and Alzheimer's Disease Phase 2 Trials at the BIO International Convention	23-05-31

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Actinogen Medical Limited

Equities

ACW

AU000000ACW3

Other languages

Filters